Meperidine Hydrochloride

證據等級: L5

預測適應症: 0 個

Meperidine Hydrochloride: Repurposing Evaluation — No TxGNN Predictions Available

One-Sentence Summary

Meperidine hydrochloride (pethidine) is a synthetic opioid analgesic historically used for moderate-to-severe pain management and pre-anesthetic sedation. This Evidence Pack contains no TxGNN repurposing predictions, and the drug is not marketed in Taiwan with zero active licenses on record. A full repurposing evaluation cannot be completed until the identified data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack
Predicted New Indication	— (No predictions generated)
TxGNN Prediction Score	—
Evidence Level	— (No predictions; below L5)
Taiwan Market Status	✗ Not Marketed
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN prediction is present in this Evidence Pack, so no formal repurposing rationale can be assessed.

Based on general pharmacological knowledge: meperidine hydrochloride is a synthetic phenylpiperidine opioid that acts primarily as a mu-opioid receptor agonist. Unlike most opioids, it also exhibits notable anticholinergic properties and a local anesthetic-like sodium channel blocking effect. It has been used clinically for acute pain, obstetric analgesia, post-operative shivering, and pre-anesthetic medication.

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, meperidine’s mu-opioid agonism and unique pharmacological profile could theoretically be relevant to indications such as treatment-resistant rigors, procedural sedation protocols, or neuropathic pain — areas where opioids with additional receptor activities have been explored. However, without a formal TxGNN prediction score, this remains entirely speculative and should not be used as a basis for evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack.

Literature Evidence

Currently no related literature available in this Evidence Pack.

Taiwan Market Information

Meperidine hydrochloride is not currently marketed in Taiwan. No active drug licenses are on record (0 DINs).

Note: Meperidine is classified as a Schedule II controlled narcotic in most jurisdictions, including Taiwan. Any future regulatory pathway would require engagement with controlled substance approval processes, which are separate from standard drug licensing.

Safety Considerations

Please refer to the package insert for safety information.

Important: All safety fields in this Evidence Pack are data gaps — key warnings, contraindications, and drug-drug interaction data are all absent. For a controlled substance opioid with a known narrow therapeutic index, respiratory depression risk, and serotonergic interaction potential (risk of serotonin syndrome with MAOIs), this is a blocking gap that must be resolved before any clinical evaluation step can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack yields no actionable repurposing signal — TxGNN generated no predictions, DrugBank ID is unresolved, the drug has no Taiwan market presence, and all safety data fields are empty. There is no basis to advance this candidate in its current state.

To proceed, the following is needed:

DrugBank ID resolution: Query DrugBank API to retrieve the correct drugbank_id for meperidine hydrochloride, which is a prerequisite for MOA retrieval and safety data population
TxGNN model run: Execute the repurposing prediction pipeline with a valid DrugBank ID to generate prediction scores and candidate indications
Original indication data: Populate original_indications from TFDA or international sources (e.g., WHO INN records, FDA label)
Safety data: Retrieve key warnings, contraindications, and DDI profile — especially critical for a controlled opioid with known serotonin syndrome risk (MAOIs), CNS depression risk (benzodiazepines, alcohol), and accumulation risk of the active metabolite normeperidine
Taiwan regulatory pathway assessment: Confirm whether meperidine is registered under Taiwan’s Controlled Drugs Act and what regulatory pathway would apply to any new indication application
Re-run Evidence Pack generation once the above gaps are resolved, targeting at minimum L4 evidence before proceeding to a Go/Proceed decision
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.